{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:27:36Z","timestamp":1793219256796,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1053\/j.gastro.2006.11.041","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T10:28:11Z","timestamp":1164882491000},"page":"52-65","source":"Crossref","is-referenced-by-count":1904,"title":["Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn\u2019s Disease: The CHARM Trial"],"prefix":"10.1053","volume":"132","author":[{"given":"Jean\u2013Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Enns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Byczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2006.11.041_bib1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1053\/gast.2000.18160","article-title":"Tumor necrosis factor: biology and therapeutic inhibitors","volume":"119","author":"Papadakis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2006.11.041_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn\u2019s disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2006.11.041_bib3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2006.11.041_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2006.11.041_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2006.11.041_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2006.11.041_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2006.11.041_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2006.11.041_bib9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2006.11.041_bib10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2006.11.041_bib11","first-page":"A731","article-title":"Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2006.11.041_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib13","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"den Broeder","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib14","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2006.11.041_bib16","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2006.11.041_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03009740410005467","article-title":"Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate","volume":"33","author":"Rau","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib18","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","article-title":"Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study","volume":"62","author":"van de Putte","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2006.11.041_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2006.11.041_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2006.11.041_bib21","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2006.11.041_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","article-title":"Adalimumab reduces spinal symptoms in active ankylosing spondylitis","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2006.11.041_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cyto.2006.01.004","article-title":"Anti-TNF-alpha therapy in ankylosis spondylitis","volume":"33","author":"De Keyser","year":"2006","journal-title":"Cytokine"},{"key":"10.1053\/j.gastro.2006.11.041_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2005.06816.x","article-title":"The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques","volume":"153","author":"Gordon","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl VII","key":"10.1053\/j.gastro.2006.11.041_bib26","first-page":"A81","article-title":"Maintenance of remission over 1 year in patients with active Crohn\u2019s disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study (oral presentation OP-G-353)","volume":"54","author":"Sandborn","year":"2005","journal-title":"Gut"},{"issue":"Suppl VII","key":"10.1053\/j.gastro.2006.11.041_bib27","first-page":"A18","article-title":"Clinical remission and response in patients with Crohn\u2019s disease treated with open-label for 1 year with fully human anti-TNF-\u03b1 monoclonal antibody adalimumab (oral presentation OP-G-78)","volume":"54","author":"Sandborn","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2006.11.041_bib28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1440-1746.2005.03848.x","article-title":"Successful treatment with adalimumab in infliximab-resistant Crohn\u2019s disease","volume":"20","author":"Barthel","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohn\u2019s disease patients with an attenuated response to infliximab","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2006.11.041_bib30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200406000-00018","article-title":"Severe anaphylactic reaction to infliximab: successful treatment with adalimumab\u2014report of a case","volume":"16","author":"Sandborn","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib31","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn\u2019s disease","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2006.11.041_bib32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200406000-00018","article-title":"Severe anaphylactic reaction to infliximab: successful treatment with adalimumab\u2014report of a case","volume":"16","author":"Stallmach","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2006.11.041_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00054725-200407000-00002","article-title":"A pilot study of adalimumab in infliximab-allergic patients","volume":"10","author":"Youdim","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"9 Suppl","key":"10.1053\/j.gastro.2006.11.041_bib34","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.14309\/00000434-200609001-01147","article-title":"Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn\u2019s disease who had secondary failure to infliximab therapy: results of the GAIN Study","volume":"101","author":"Sandborn","year":"2006","journal-title":"Ann J Gastroenterol"},{"issue":"Suppl II","key":"10.1053\/j.gastro.2006.11.041_bib35","first-page":"181","article-title":"Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis (abstr)","volume":"65","author":"Burmester","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2006.11.041_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analysis of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508506025224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508506025224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:37:08Z","timestamp":1587256628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508506025224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0016508506025224"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2006.11.041","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1077751.530664","asserted-by":"object"}]},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}